Shots:
Amgen & AZ have reported the P-III (DeLLphi-305) trial data assessing Imfinzi + Imdelltra vs Imfinzi as the 1L maintenance treatment for pts (n=563) with ES-SCLC who have not progressed following induction treatment with Imfinzi + PT-based CT & etoposide
Trial showed improved OS (1EP) & demonstrated benefits across 2EPs, incl. PFS & ORR;…
